# GPR3 in Neuro-Metabolic-Immune-Reproductive Nexus: Potential Therapeutic Target > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/gpr3-neuro-metabolic-immune-nexus-therapeutic-target/ > **Published:** 2026-03-26T15:05:54-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:37:24-04:00 > **Clinical Summary:** Explore GPR3 neuro-metabolic immune nexus as a promising therapeutic target for multisystem diseases affecting brain, metabolism, immunity, and reproduction. --- CED Clinical Relevance  #50Monitored Relevance  Early-stage or contextual signal requiring further evidence before action. 🔬 Evidence Watch  |  CED Clinic NeurologyMetabolismGpcrMultisystemBasic Science Journal Annals of medicine Study Type Clinical Study Population Human participants Why This Matters GPR3 represents an emerging therapeutic target that may explain interconnections between neurological, metabolic, immune, and reproductive disorders that [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) practitioners frequently encounter in complex patient presentations. Understanding this receptor’s multisystem influence could inform more targeted cannabinoid therapeutic approaches for patients with comorbid conditions. Clinical Summary This systematic review synthesizes evidence on GPR3, an orphan G-protein-coupled receptor with constitutive activity across brain, liver, ovary, and other tissues. The authors examined GPR3’s role in regulating cell proliferation, differentiation, and apoptosis across nervous, reproductive, immune, and metabolic systems through literature analysis from PubMed and Web of Science databases. Key findings highlight GPR3’s involvement in neuronal survival, synaptic plasticity, microglial function, immune inflammation, reproductive processes, and energy metabolism. The review identifies GPR3 as a potential therapeutic target for multisystem diseases, though specific clinical applications remain to be validated through controlled studies. Dr. Caplan’s Take “While this receptor biology is fascinating, I remain focused on established [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) targets where we have robust clinical evidence. GPR3 research may eventually inform [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) practice, but currently represents basic science rather than actionable clinical intelligence.” Clinical Perspective 🧠 Clinicians should note this as foundational research that may eventually impact therapeutic decision-making but should continue relying on established cannabinoid mechanisms and clinical evidence for current [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/). Patients with multisystem presentations may benefit from this emerging understanding in future therapeutic developments, but immediate treatment decisions should remain grounded in proven cannabinoid pathways. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20GPR3%20in%20neuro-metabolic-immune-reproductive%20nexus%20-%20a%20potential%20therapeutic%20targ...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41574602/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41574602/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20GPR3%20in%20neuro-metabolic-immune-reproductive%20nexus%20-%20a%20potential%20therapeutic%20targ...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41574602/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41574602/](https://pubmed.ncbi.nlm.nih.gov/41574602/) Table of Contents - [FAQ](#FAQ)[What is GPR3 and why is it clinically significant?](#What_is_GPR3_and_why_is_it_clinically_significant) - [How does GPR3 relate to neurological conditions?](#How_does_GPR3_relate_to_neurological_conditions) - [What role does GPR3 play in metabolic health?](#What_role_does_GPR3_play_in_metabolic_health) - [How does GPR3 affect immune and inflammatory responses?](#How_does_GPR3_affect_immune_and_inflammatory_responses) - [What are the current therapeutic implications of GPR3 research?](#What_are_the_current_therapeutic_implications_of_GPR3_research) - [Related](#Related) ## FAQ #### What is GPR3 and why is it clinically significant? GPR3 is an orphan G-protein-coupled receptor with constitutive Gs activity that regulates cell proliferation, differentiation, and apoptosis across multiple organ systems. It’s expressed in the brain, liver, ovary, and other tissues, making it a potential therapeutic target for neurodegenerative diseases, metabolic disorders, immune dysfunction, and reproductive health conditions. #### How does GPR3 relate to neurological conditions? GPR3 plays crucial roles in neuronal survival and synaptic plasticity, with involvement in neurodegenerative disease processes. The receptor’s activity in brain tissue suggests it may be a therapeutic target for conditions affecting [cognitive function](https://cedclinic.com/reverse-cholesterol-transport-function-cannabis-users/) and neuronal health. #### What role does GPR3 play in metabolic health? GPR3 is involved in energy metabolism regulation through its expression in metabolically active tissues like the liver. Its signaling pathways may influence metabolic processes, making it relevant for understanding and potentially treating metabolic disorders. #### How does GPR3 affect immune and inflammatory responses? Research indicates GPR3 involvement in immune inflammation processes, suggesting it may modulate [immune system function](https://cedclinic.com/cannabinoid-receptor-type-1-antagonist-obesity-steatohepatitis/). This multisystem activity positions GPR3 as a potential target for inflammatory conditions that span multiple organ systems. #### What are the current therapeutic implications of GPR3 research? While GPR3 shows promise as a therapeutic target due to its multisystem involvement, current evidence remains at the early research stage. Further clinical studies are needed to establish specific therapeutic applications and develop targeted agonists or inhibitors for clinical use. {“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “GPR3 in neuro-metabolic-immune-reproductive nexus – a potential therapeutic target for Multi-System diseases.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41574602/”, “about”: “annals medicine clinical study gpr3 neuro”, “isPartOf”: “Annals of medicine”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Letter by Wu et al Regarding Article, "G Protein-Coupled Receptor Kinase 3 Exacerbates Diabetic Heart Injuries"](https://cedclinic.com/cannabinoid-receptor-2-phosphorylation-diabetic-heart-injury/) Explore insights on G protein-coupled receptor kinase 3 and its role in diabetic heart injuries, complementing GPR3 receptor research. [Read More](https://cedclinic.com/cannabinoid-receptor-2-phosphorylation-diabetic-heart-injury/) [Cannabinoid Therapies in Less-Common Disorders: Clinical Evidence and Formulation Strategies](https://cedclinic.com/cannabinoid-therapies-rare-diseases-evidence-formulation/) Review clinical evidence and formulation strategies for cannabinoid therapies in complex multisystem disorders. [Explore Now](https://cedclinic.com/cannabinoid-therapies-rare-diseases-evidence-formulation/) [Progressive Endocannabinoid System Dysregulation in Autosomal Dominant Polycystic Kidney Disease](https://cedclinic.com/endocannabinoid-system-dysfunction-adpkd/) Understand [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) dysregulation in kidney disease, relevant to multisystem receptor targets like GPR3. [Learn More](https://cedclinic.com/endocannabinoid-system-dysfunction-adpkd/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).